ATHX / Athersys (ATHX) Down as Ischemic Stroke Study Fails to Meet Goal

Longevity stocks have started to come on many investors' radars. These companies come with the promise of stable returns over the long run as human li more_horizontal

The traditional approach to investing is finding well-established companies, investing in them and waiting years for a return of 50%. But in today's f more_horizontal

Penny stocks, often priced under $1, have long been the allure for many investors seeking high-risk, high-reward opportunities. These stocks, typicall more_horizontal

Athersys (NASDAQ: ATHX ) stock is falling on Friday after the biotechnology company announced a public stock offering. That public offering has Ather more_horizontal

CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (NASDAQ: ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for more_horizontal

CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (NASDAQ: ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for more_horizontal

Athersys, Inc. (NASDAQ:ATHX ) Q3 2022 Earnings Conference Call November 15, 2022 11:00 AM ET Company Participants Ellen Gurley – Corporate Communica more_horizontal

While a mid-stage/late-stage study evaluating Athersys' (ATHX) stem cell treatment for ischemic stroke misses out on its primary endpoint, top-line da more_horizontal